- Home
- FTAIN vs KLTOW Comparison
FTAIN vs KLTOW Comparison
Compare FTAIN & KLTOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
FTAIN
FTAI Aviation Ltd. 8.25% Fixed - Rate Reset Series C Cumulative Perpetual Redeemable Preferred Shares
Current Price
Current Price
Company Overview
Basic Information| Metric | FTAIN | KLTOW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 580 | 3 |
| Industry | Misc Corporate Leasing Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | FTAIN | KLTOW |
|---|---|---|
| Price | $25.62 | $0.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.9K | ★ 11.5K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.34 | $0.01 |
| 52 Week High | $25.95 | $0.95 |
Technical Indicators
Market Signals| Indicator | FTAIN | KLTOW |
|---|---|---|
| Relative Strength Index (RSI) | 55.19 | 43.50 |
| Support Level | $25.56 | $0.07 |
| Resistance Level | $25.68 | $0.09 |
| Average True Range (ATR) | 0.08 | 0.01 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 62.97 | 35.26 |
Price Performance
Historical ComparisonAbout FTAIN FTAI Aviation Ltd. 8.25% Fixed - Rate Reset Series C Cumulative Perpetual Redeemable Preferred Shares
FTAI Aviation Ltd is an aerospace company. It owns and maintains commercial jet engines with a focus on CFM56 engines. FTAI owns and leases jet aircraft, which often facilitates the acquisition of engines at attractive prices. It invests in aviation assets and aerospace products that generate stable cash flows with the potential for earnings growth and asset appreciation.
About KLTOW Klotho Neurosciences Inc. Warrant
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.